The most robust results of the NPC Trial come from the recent analyses of the complete trial data for prostate cancer incidence, the diagnosis of which was confirmed by analysis of prostate-specific antigen (PSA) in the plasma (Duffield-Lillico et al, 2003a, 2003b). This evidence concerns the gene KLK3 and prostate carcinoma.